|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality
Worldwide: IARC CancerBase No. 11. IARC; Lyon, France: 2013
|
|
2
|
Mellman I, Coukos G and Dranoff G: Cancer
immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dudley ME and Rosenberg SA:
Adoptive-cell-transfer therapy for the treatment of patients with
cancer. Nat Rev Cancer. 3:666–675. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Terunuma H: Autologous immune enhancement
therapy for cancer-our experience since 2004. J Stem Cells Regen
Med. 8:205–206. 2012.PubMed/NCBI
|
|
5
|
Kalinski P, Mailliard RB, Giermasz A, Zeh
HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT and Herberman RB:
Natural killer-dendritic cell cross-talk in cancer immunotherapy.
Expert Opin Biol Ther. 5:1303–1315. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kalos M and June CH: Adoptive T cell
transfer for cancer immunotherapy in the era of synthetic biology.
Immunity. 39:49–60. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cooper MA, Fehniger TA and Caligiuri MA:
The biology of human natural killer-cell subsets. Trends Immunol.
22:633–640. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Screpanti V, Wallin RP, Ljunggren HG and
Grandien A: A central role for death receptor-mediated apoptosis in
the rejection of tumors by NK cells. J Immunol. 167:2068–2073.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bouwer AL, Saunderson SC, Caldwell FJ,
Damani TT, Pelham SJ, Dunn AC, Jack RW, Stoitzner P and McLellan
AD: NK cells are required for dendritic cell-based immunotherapy at
the time of tumor challenge. J Immunol. 192:2514–2521. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sutlu T and Alici E: Natural killer
cell-based immunotherapy in cancer: Current insights and future
prospects. J Intern Med. 266:154–181. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qin Z, Schwartzkopff J, Pradera F,
Kammertoens T, Seliger B, Pircher H and Blankenstein T: A critical
requirement of interferon gamma-mediated angiostasis for tumor
rejection by CD8+ T cells. Cancer Res. 63:4095–4100.
2003.PubMed/NCBI
|
|
12
|
Maher J and Davies ET: Targeting cytotoxic
T lymphocytes for cancer immunotherapy. Br J Cancer. 91:817–821.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Weigelin B, Krause M and Friedl P:
Cytotoxic T lymphocyte migration and effector function in the tumor
microenvironment. Immunol Lett. 138:19–21. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Anikeeva N, Somersalo K, Sims TN, Thomas
VK, Dustin ML and Sykulev Y: Distinct role of lymphocyte
function-associated antigen-1 in mediating effective cytolytic
activity by cytotoxic T lymphocytes. Proc Natl Acad Sci USA.
102:pp. 6437–6442. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ratner A and Clark WR: Role of TNF-alpha
in CD8+ cytotoxic T lymphocyte-mediated lysis. J
Immunol. 150:4303–4314. 1993.PubMed/NCBI
|
|
16
|
Castriconi R, Daga A, Dondero A, Zona G,
Poliani PL, Melotti A, Griffero F, Marubbi D, Spaziante R, Bellora
F, et al: NK cells recognize and kill human glioblastoma cells with
stem cell-like properties. J Immunol. 182:3530–3539. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weng D, Song B, Durfee J, Sugiyama V, Wu
Z, Koido S, Calderwood SK and Gong J: Induction of cytotoxic T
lymphocytes against ovarian cancer-initiating cells. Int J Cancer.
129:1990–2001. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ahmed N, Salsman VS, Kew Y, Shaffer D,
Powell S, Zhang YJ, Grossman RG, Heslop HE and Gottschalk S:
HER2-specific T cells target primary glioblastoma stem cells and
induce regression of autologous experimental tumors. Clin Cancer
Res. 16:474–485. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cho D and Campana D: Expansion and
activation of natural killer cells for cancer immunotherapy. Korean
J Lab Med. 29:89–96. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Carlens S, Gilljam M, Chambers BJ, Aschan
J, Guven H, Ljunggren HG, Christensson B and Dilber MS: A new
method for in vitro expansion of cytotoxic human
CD3-CD56+ natural killer cells. Hum Immunol.
62:1092–1098. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fujisaki H, Kakuda H, Shimasaki N, Imai C,
Ma J, Lockey T, Eldridge P, Leung WH and Campana D: Expansion of
highly cytotoxic human natural killer cells for cancer cell
therapy. Cancer Res. 69:4010–4017. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Torelli GF, Rozera C, Santodonato L,
Peragine N, D'agostino G, Montefiore E, Napolitano MR, Monque DM,
Carlei D, Mariglia P, et al: A good manufacturing practice method
to ex vivo expand natural killer cells for clinical use. Blood
Transfus. 13:464–471. 2015.PubMed/NCBI
|
|
23
|
Koehl U, Brehm C, Huenecke S, Zimmermann
SY, Kloess S, Bremm M, Ullrich E, Soerensen J, Quaiser A, Erben S,
et al: Clinical grade purification and expansion of NK cell
products for an optimized manufacturing protocol. Front Oncol.
3:1182013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Subramani B, Ratnavelu K, Pullai CR,
Krishnan K, Sugadan SD, Deng X and Hiroshi T: Autologous immune
enhancement therapy: A case report of a stage IV colonic cancer.
Oncol Lett. 5:1611–1614. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dedeepiya V, Terunuma H, Manjunath S,
Senthilkumar R, Thamaraikannan P, Srinivasan T, HelenReena C,
Preethy S and Abraham S: Autologous immune enhancement therapy for
cancer using NK cells and CTLs without feeder layers; our six year
experience in India. J Stem Cells Regen Med. 7:952011.PubMed/NCBI
|
|
26
|
Terunuma H, Deng X, Nishino N and Watanabe
K: NK cell-based autologous immune enhancement therapy (AIET) for
cancer. J Stem Cells Regen Med. 9:9–13. 2013.PubMed/NCBI
|
|
27
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Topalian SL, Muul LM, Solomon D and
Rosenberg SA: Expansion of human tumor infiltrating lymphocytes for
use in immunotherapy trials. J Immunol Methods. 102:127–141. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dudley ME, Wunderlich JR, Shelton TE, Even
J and Rosenberg SA: Generation of tumor-infiltrating lymphocyte
cultures for use in adoptive transfer therapy for melanoma
patients. J Immunother. 26:332–342. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Porter DL, Levine BL, Bunin N, Stadtmauer
EA, Luger SM, Goldstein S, Loren A, Phillips J, Nasta S, Perl A, et
al: A phase 1 trial of donor lymphocyte infusions expanded and
activated ex vivo via CD3/CD28 costimulation. Blood. 107:1325–1331.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rasmussen AM, Borelli G, Hoel HJ, Lislerud
K, Gaudernack G, Kvalheim G and Aarvak T: Ex vivo expansion
protocol for human tumor specific T cells for adoptive T cell
therapy. J Immunol Methods. 355:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Smith C, Økern G, Rehan S, Beagley L, Lee
SK, Aarvak T, Schjetne KW and Khanna R: Ex vivo expansion of human
T cells for adoptive immunotherapy using the novel Xeno-free CTS
immune cell serum replacement. Clin Transl Immunol. 4:e312015.
View Article : Google Scholar
|
|
33
|
Michel T, Poli A, Cuapio A, Briquemont B,
Iserentant G, Ollert M and Zimmer J: Human CD56bright NK Cells: An
Update. J Immunol. 196:2923–2931. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chan A, Hong DL, Atzberger A, Kollnberger
S, Filer AD, Buckley CD, McMichael A, Enver T and Bowness P:
CD56bright human NK cells differentiate into CD56dim
cells: Role of contact with peripheral fibroblasts. J Immunol.
179:89–94. 2007. View Article : Google Scholar : PubMed/NCBI
|
